Perspective Therapeutics, Inc. logo CATX - Perspective Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 9
HOLD 2
SELL 0
STRONG
SELL 0
| PRICE TARGET: $13.33 DETAILS
HIGH: $16.00
LOW: $12.00
MEDIAN: $12.00
CONSENSUS: $13.33
UPSIDE: 234.92%

Stock News

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updates on all three of its advancing clinical programs, [²¹²Pb]VMT-α-NET, [²¹²Pb]VMT01, and [²¹²Pb]PSV359, will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, IL.

May 21, 2026 01:51 PM • globenewswire.com
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

SEATTLE, May 18, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the first patients were dosed with [212Pb]VMT-α-NET and [212Pb]PSV359 in two new cohorts of Phase 1/2a studies in neuroendocrine tumors and solid tumors, respectively.

May 18, 2026 02:30 AM • globenewswire.com
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results

SEATTLE, May 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended March 31, 2026.

May 11, 2026 12:07 PM • globenewswire.com
Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field

Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field

Perspective Therapeutics (CATX) is advancing radiopharmaceutical therapies, with a pivotal data readouts expected in 2026 in NETs, plus melanoma / solid tumor data. CATX's VMT-α-NET shows promising early efficacy in SSTR2-positive neuroendocrine tumors, with 76% of patients alive and progression-free in a 25-patient study. Sanofi's discontinuation of Alphamedix and promising comparison withy Novartis' Lutathera highlight significant market opportunity for CATX's pipeline.

Apr 27, 2026 02:28 PM • seekingalpha.com
Perspective Therapeutics to Provide Several Upcoming Corporate Updates

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

SEATTLE, April 24, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will provide several corporate updates in May 2026. Webcasts of these events, unless noted as press release only, will be posted on the Company's website at www.perspectivetherapeutics.com.

Apr 24, 2026 02:30 AM • globenewswire.com
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

SEATTLE, April 20, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs) as part of a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026. [212Pb]VMT-α-NET is potentially the first-in-class 212Pb-radiopharmaceutical therapy targeting SSTR2.

Apr 20, 2026 02:00 AM • globenewswire.com
Perspective Therapeutics to Participate in Upcoming Investor Conferences

Perspective Therapeutics to Participate in Upcoming Investor Conferences

SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences:

Apr 02, 2026 03:00 AM • globenewswire.com
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

SEATTLE, March 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [212Pb]VMT-α-NET program have been accepted as a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place from April 17 to 22, 2026 in San Diego, CA as detailed below. AACR has announced that it will release further details for clinical trial abstracts for the conference on April 17, 2026.

Mar 17, 2026 12:45 PM • globenewswire.com
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

SEATTLE, March 16, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today provided a business update and announced full year results for the year ended December 31, 2025.

Mar 16, 2026 12:07 PM • globenewswire.com
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its full year 2025 financial results and provide a business update on Monday, March 16, 2025 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.

Feb 17, 2026 02:00 AM • globenewswire.com
Profusa (NASDAQ:PFSA) and Perspective Therapeutics (NASDAQ:CATX) Financial Contrast

Profusa (NASDAQ:PFSA) and Perspective Therapeutics (NASDAQ:CATX) Financial Contrast

Perspective Therapeutics (NASDAQ: CATX - Get Free Report) and Profusa (NASDAQ: PFSA - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability. Insider and Institutional Ownership 54.7% of Perspective Therapeutics

Feb 06, 2026 08:08 PM • defenseworld.net
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

SEATTLE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today announced the pricing of an underwritten offering of 39,576,088 shares of its common stock at an offering price of $3.79 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 6,598,046 shares of its common stock at a price of $3.789 per pre-funded warrant. The aggregate gross proceeds from this offering are expected to be approximately $175 million, before deducting underwriting discounts and commissions and other offering expenses payable by Perspective in connection with the offering. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, minus the $0.001 per share exercise price of such pre-funded warrant. The offering is expected to close on or about February 3, 2026, subject to the satisfaction of customary closing conditions. All of the shares of common stock and pre-funded warrants to be sold in the offering are being sold by Perspective.

Feb 02, 2026 03:35 AM • globenewswire.com
Comparing Perspective Therapeutics (NASDAQ:CATX) & Biosig Technologies (NASDAQ:STEX)

Comparing Perspective Therapeutics (NASDAQ:CATX) & Biosig Technologies (NASDAQ:STEX)

Biosig Technologies (NASDAQ: STEX - Get Free Report) and Perspective Therapeutics (NASDAQ: CATX - Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends. Valuation and Earnings This table compares Biosig

Feb 01, 2026 09:00 PM • defenseworld.net
Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space

Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space

Perspective Therapeutics, Inc. retains a Strong Buy rating, driven by promising VMT-a-NET data and Sanofi deprioritizing a competing SSTR2-targeted therapy. CATX's VMT-a-NET achieved 76% progression-free and alive status in SSTR2 NET patients, with pivotal mid-2026 data readouts expected to drive further value. Upcoming catalysts include full 48-week cohort 2 data, higher-dose cohort 3 results, and additional pipeline readouts for VMT01 and PSV359 in 2026.

Jan 30, 2026 10:37 AM • seekingalpha.com

Price Targets